Introduction {#Sec1}
============

The randomised controlled trial (RCT) remains the primary design for evaluating the marginal (population average) causal effect of a treatment, *i*.*e*., the average treatment effect between two hypothetical worlds where: i) everyone is treated and ii) everyone is untreated^[@CR1]^. Indeed, a well-designed RCT with a sufficient sample size ensures the baseline comparability between groups, thus allowing the estimation of a marginal causal effect. Nevertheless, it is well established that RCT is performed under optimal circumstances (*e*.*g*., over-representation of treatment-adherent patients, low frequency of morbidity), which may be different from real-life practices^[@CR2]^. Observational studies have the advantage of limiting the issue of external validity, but treated and untreated patients are often non-comparable, leading to a high risk of confounding bias.

To reduce such confounding bias, the vast majority of observational studies have been based on multivariable models (mainly linear, logistic, or Cox models), allowing for the direct estimation of conditional (subject-specific) effects, *i*.*e*., the average effect across sub-populations of subjects who share the same characteristics. Several methods have been proposed to estimate marginal causal effects in observational studies, amongst which propensity score (PS)-based methods are increasingly used in epidemiology and medical research^[@CR3]^.

Propensity score-based methods make use of the PS in four different ways to account for confounding, namely matching, stratification, conditional adjustment^[@CR4]^ and inverse probability of treatment weighting (IPTW)^[@CR5]^. Stratification and conditional adjustment on PS are associated with the highest bias^[@CR6]--[@CR8]^, because the two methods estimate the conditional treatment effect rather than the marginal causal effect. Matching on PS remains the most common approach with a usage rate of 83.8% in 303 surgical studies using PS-based methods^[@CR9]^ and 68.9% in 296 medical studies (without restriction regarding the field) also using PS-methods^[@CR10]^. The IPTW appears to be less biased and associated with a lower variance than matching in several studies^[@CR8],[@CR11]--[@CR14]^. Nevertheless, in particular settings, full matching (FM) was associated with lower mean square error (MSE) in other studies^[@CR15]--[@CR17]^.

Multivariable models, even non-linear ones, can also be used to indirectly estimate the marginal causal effect with g-computation (GC)^[@CR18]^. This method is also called the parametric g-formula^[@CR1]^ or (g-)standardisation^[@CR19]^ in the literature. Snowden *et al*.^[@CR20]^ and Wang *et al*.^[@CR21]^ detailed the corresponding methodology for estimating the average treatment (*i*.*e*., marginal causal) effect on the entire population (ATE) or only on the treated (ATT), respectively. The ATE is the average effect, at the population level, of moving an entire population from untreated to treated. The ATT is the average effect of treatment on those subjects who ultimately received the treatment^[@CR22]^. Furthermore, some authors^[@CR23],[@CR24]^ have proposed combinations of GC and PS to improve the estimation of the marginal causal effect. These methods are known as doubly robust estimators (DRE) because they require the specification of both the outcome (for GC) and treatment allocation (for PS) mechanisms to minimise the impact of model misspecification. Indeed, these estimators are consistent as long as either the outcome model or the treatment model is estimated correctly^[@CR25]^.

Each of these methods carries out the adjustment in different ways, but all of these methods rely on the same condition: a correct specification of the PS or the outcome model^[@CR1]^. In practice, a common issue is choosing the set of covariates to include to obtain the best performance in terms of bias and precision. Three simulation studies^[@CR7],[@CR26],[@CR27]^ have investigated this issue for PS-based methods. They studied four sets of covariates: those causing the outcome, those causing the treatment allocation, those are a common cause of both the treatment allocation and the outcome, and all the covariates. For the rest of this paper, we called these strategies the *outcome set*, the *treatment set*, the *common set* and the *entire set*, respectively. These studies argued in favour of the outcome or common sets for PS-based methods, but it is not immediately clear that such works will generalise to other methods of causal inference. Brookhart *et al*.^[@CR26]^ and Lefebvre *et al*.^[@CR27]^ focused on count and continuous outcomes. Austin *et al*.^[@CR7]^ investigated binary outcomes on matching, stratification and adjustment on PS. However, GC and DRE also require the correct specification of the outcome model with a potentially different set of covariates. Recent works have shown that efficiency losses can accompany the inclusion of unnecessary covariates^[@CR28]--[@CR31]^. De Luna *et al*.^[@CR32]^ also highlighted the variance inflation caused by the treatment set. In contrast, VanderWeele and Shpitser^[@CR33]^ suggested the inclusion of both the outcome and the treatment sets.

Before selecting the set of covariates, one needs to select the method to employ. Several studies have compared the performances of GC, PS-based methods and DRE in a point treatment study to estimate the ATE^[@CR13],[@CR23],[@CR25],[@CR34]--[@CR36]^. Half of these studies investigated a binary outcome^[@CR13],[@CR25],[@CR34]^. Only Colson *et al*.^[@CR17]^ studied the ATT, but they focused on a continuous outcome. Except in Neugebauer and van der Laan^[@CR25]^, these studies only investigated the ATE (or ATT) defined as a risk difference. The CONSORT recommended the presentation of both the absolute and the relative effect sizes for a binary outcome, "*as neither the relative measure nor the absolute measure alone gives a complete picture of the effect and its implications*"^[@CR37]^. None of these studies was interested in the set of covariates necessary to obtain the best performance.

In our study, we sought to compare different sets of covariates to consider to estimate a marginal causal effect. Moreover, we compared GC, PS-based methods and DRE for both the ATE and ATT, either in terms of risk difference or marginal causal OR. Three main types of outcome are used in epidemiology and medical research: continuous, binary and time-to-event outcomes. We focused on a binary outcome because i) a continuous outcome is often appealing for linear regression where the two conditional and marginal causal effects are collapsible^[@CR38]^, and ii) time-to-event analyses present additional methodological difficulties, such as the time-dependant covariate distribution^[@CR39]^. We also limit our study to a binary treatment, as in the current literature, and the extension to three or more modalities is beyond the scope of our study.

The paper is structured as follows. In the next section, the methods are detailed. The third section presents the design and results of the simulations. In the fourth section, we consider two real data sets. Finally, we discuss our results in the last section.

Methods {#Sec2}
=======

Setting and notations {#Sec3}
---------------------
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Causal inference requires the three following assumptions, called *identifiability conditions*: i) The values of exposure under comparisons correspond to well-defined interventions that, in turn, correspond to the versions of treatment in the data. ii) The conditional probability of receiving every value of treatment, though not decided by the investigators, depends only on the measured covariates. iii) The conditional probability of receiving every value of the treatment is greater than zero, *i*.*e*., is positive. These assumptions are known as *consistency*, *(conditional) exchangeability* and *positivity*, respectively^[@CR1]^. However, PS-based methods rely on treatment allocation modelling to obtain a pseudo-population in which the confounders are balanced across treatment groups. Covariate balance can be checked by computing the standardised difference of the covariates included in the PS between the two treatment groups^[@CR10]^. In contrast, GC relies on outcome modelling to predict hypothetical outcomes for each subject under each treatment regimen. Note that one can ignore the lack of positivity if one is willing to rely on Q-model extrapolation^[@CR1]^. As is the case for standard regression models, these methods also require the assumptions of no interference, no measurement error and no model misspecification.

Weighting on the inverse of the propensity score {#Sec4}
------------------------------------------------
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Full Matching on the propensity score {#Sec5}
-------------------------------------

The FM minimises the average within-stratum differences in the PS between treated and untreated subjects^[@CR16]^. Then, two weighting systems can be applied in each stratum, making it possible to estimate either the ATE or the ATT unlike other matching methods which can only estimate the ATT^[@CR44]^. If $\documentclass[12pt]{minimal}
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G-computation {#Sec6}
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Targeted Maximum Likelihood Estimator {#Sec7}
-------------------------------------

Amongst the several existing DREs, we focused on the targeted maximum likelihood estimator (TMLE)^[@CR24]^, for which estimators of ATE and ATT have been proposed^[@CR47]^. The TMLE begins by fitting the Q-model to estimate the two expected hypothetical probabilities of events $\documentclass[12pt]{minimal}
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Simulation study {#Sec8}
================

Design {#Sec9}
------

We used a close data generating procedure from previous studies on PS models^[@CR7],[@CR50]^. We generated the data in three steps. i) Nine covariates (*L*~1~, ..., *L*~9~) were independently simulated from a Bernoulli distribution with a parameter equal to 0.5 for all covariates. ii) We generated the treatment $\documentclass[12pt]{minimal}
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                \begin{document}$${L}_{1}$$\end{document}$ in the PS or in the Q-model to evaluate the impact of an unmeasured confounder. We performed all the analyses using R version 3.6.0^[@CR52]^.Figure 1Causal diagram. Solid lines corresponded to a strong association (OR = 6.0) and dashed lines to a moderate one (OR = 1.5).

Results {#Sec10}
=======

Convergence {#Sec11}
-----------

Non-convergence only occurred for ATT estimation when sample sizes were lower or equal to 300 subjects (see Fig. [2](#Fig2){ref-type="fig"}). The GC, IPTW and FM had a minimal convergence percentage higher than 98%, even under small sample size (n = 100). Similarly, TMLE experienced some difficulty in converging for ATT estimation in the medium-sized sample (n = 300). However, they experienced severe difficulty in converging in the small sample with a convergence percentage of approximately 92%.Figure 2Percentage of simulation iterations which did not converge according to the methods.

Mean bias {#Sec12}
---------

As expected with the common set, the mean absolute bias of $\documentclass[12pt]{minimal}
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                \begin{document}$$\theta $$\end{document}$ was close to zero for GC, IPTW and TMLE when the three identifiability assumptions hold with a maximum at −0.028 given moderate sample size (n = 300) under the alternative hypothesis for ATT estimation (Table [1](#Tab1){ref-type="table"}). Note that the three other covariate sets led to a bias close to zero with a maximum of 0.053 for TMLE with the entire set given small sample size (n = 100) under the alternative hypothesis for ATE estimation (Table [2](#Tab2){ref-type="table"}). Furthermore, FM was also associated with a similar bias with a maximum of 0.082 given a small sample size (n = 100), with the treatment set under the alternative hypothesis for the ATE estimation. With an unmeasured confounder, the bias increased in all scenarios with a minimum of 0.456 for GC with the common set given a large sample size for the ATT estimation (see Online Supporting Information ([OSI)](#MOESM1){ref-type="media"} for complete results). The results were similar under the null hypothesis (see [OSI](#MOESM1){ref-type="media"}).Table 1Simulation results comparing the ATT estimation under the alternative hypothesis.nmethodselection strategymean biaslog OR*π*~0~*π*~1~Δ*π*log ORMSEMSE\*VEB (%)coverage (%)power (%)100GCoutcome0.000−0.001−0.0010.0120.5260.716−6.294.117.7treatment0.002−0.001−0.0030.0060.5800.786−5.794.114.0common0.002−0.001−0.0030.0060.5520.735−4.294.815.1entire−0.001−0.001−0.0010.0130.5580.768−8.893.316.9IPTWoutcome0.000−0.001−0.0010.0080.5780.72710.897.37.8treatment−0.000−0.001−0.0010.0000.7160.837−1.295.19.8common0.002−0.001−0.0030.0030.5870.7436.696.88.8entire−0.003−0.0010.0020.0050.7410.838−1.595.29.6TMLEoutcome−0.001−0.0010.0000.0020.6940.79430.095.75.8treatment0.000−0.001−0.001−0.0200.8760.955183.398.81.0common−0.000−0.001−0.001−0.0010.7020.79410.495.37.3entire−0.003−0.0010.001−0.0130.8860.953412.298.80.5FMoutcome−0.004−0.0010.0030.0220.6650.787−16.790.118.9treatment−0.006−0.0010.0040.0170.8220.911−32.381.325.2common−0.001−0.001−0.0000.0100.6530.795−15.391.017.5entire−0.008−0.0010.0060.0220.8420.921−33.880.326.7300GCoutcome0.001−0.001−0.002−0.0210.2830.555−1.694.543.6treatment0.002−0.001−0.003−0.0240.3190.606−2.394.335.2common0.002−0.001−0.003−0.0230.3040.561−1.594.838.5entire0.001−0.001−0.002−0.0220.2970.600−2.694.039.9IPTWoutcome0.002−0.001−0.003−0.0270.3010.55616.497.924.0treatment0.001−0.001−0.002−0.0260.3720.6286.696.221.4common0.003−0.001−0.004−0.0280.3180.5639.196.826.1entire0.001−0.001−0.002−0.0250.3610.62211.797.220.0TMLEoutcome0.000−0.001−0.001−0.0230.3580.577−2.393.629.0treatment0.002−0.001−0.003−0.0350.4540.68351.299.16.8common0.001−0.001−0.002−0.0230.3780.582−3.593.026.5entire0.002−0.001−0.003−0.0350.4320.67481.899.34.4FMoutcome−0.000−0.001−0.001−0.0200.3510.579−11.791.937.2treatment−0.001−0.001−0.000−0.0220.4440.656−30.282.738.9common0.001−0.001−0.002−0.0240.3630.587−14.690.436.9entire−0.001−0.0010.000−0.0200.4390.662−29.383.239.1500GCoutcome0.001−0.001−0.002−0.0140.2170.509−1.194.764.5treatment0.001−0.001−0.002−0.0140.2450.556−1.594.453.6common0.001−0.001−0.002−0.0150.2330.618−0.894.857.6entire0.001−0.001−0.002−0.0140.2280.552−2.094.260.5IPTWoutcome0.002−0.001−0.003−0.0190.2300.50916.597.943.3treatment0.000−0.001−0.001−0.0130.2850.5746.896.635.4common0.002−0.001−0.003−0.0180.2440.5149.296.843.7entire0.000−0.001−0.001−0.0140.2740.57112.397.233.9TMLEoutcome0.001−0.001−0.002−0.0150.2720.521−4.793.448.5treatment0.001−0.001−0.002−0.0180.3470.61835.099.115.9common0.000−0.001−0.001−0.0130.2890.527−4.893.143.7entire0.001−0.001−0.002−0.0190.3280.61151.199.312.9FMoutcome0.001−0.001−0.002−0.0150.2650.525−9.992.453.0treatment−0.001−0.001−0.000−0.0110.3460.597−31.082.751.7common0.001−0.001−0.001−0.0140.2830.530−15.890.152.3entire−0.002−0.0010.001−0.0080.3400.596−29.883.252.62000GCoutcome0.0000.000−0.000−0.0020.1080.479−1.794.799.6treatment0.0010.000−0.000−0.0030.1220.524−1.294.898.6common0.0010.000−0.000−0.0030.1160.480−0.994.799.1entire0.0000.000−0.000−0.0020.1130.523−1.894.599.4IPTWoutcome0.0020.000−0.001−0.0060.1130.47816.397.698.1treatment0.0000.000−0.000−0.0020.1380.5397.996.493.0common0.0020.000−0.001−0.0060.1200.4809.497.097.7entire0.0000.000−0.000−0.0020.1310.53713.997.493.62000TMLEoutcome0.0010.000−0.000−0.0020.1320.483−5.993.397.5treatment0.0000.0000.000−0.0020.1690.56818.298.271.8common−0.0000.0000.000−0.0000.1420.486−5.693.695.5entire0.0010.000−0.000−0.0040.1580.56523.598.675.3FMoutcome0.0000.000−0.000−0.0020.1340.484−12.091.697.7treatment0.0010.000−0.000−0.0050.2030.548−41.674.689.9common0.0010.000−0.000−0.0030.1490.485−20.588.596.7entire0.0000.0000.000−0.0020.1620.543−26.984.594.8\*MSE in the presence of an unmeasured confounder. Theoretical values: $\documentclass[12pt]{minimal}
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                \begin{document}$${\pi }_{1}=0.701,{\pi }_{0}=0.589,\theta =0.492$$\end{document}$.Table 2Simulation results comparing the ATE estimation under the alternative hypothesis.nmethodsetmean biaslog OR*π*~0~*π*~1~Δ*π*log ORMSEMSE\*VEB (%)coverage (%)power (%)100GCoutcome−0.001−0.002−0.001−0.0030.4040.634−7.393.224.7treatment−0.002−0.0010.0000.0040.4770.727−9.592.419.9common−0.001−0.002−0.001−0.0020.4340.650−6.693.522.1entire−0.002−0.0010.0010.0030.4500.714−11.491.822.6IPTWoutcome−0.003−0.0010.0010.0110.4640.64612.197.412.1treatment−0.0060.0020.0080.0460.6330.769−7.693.816.7common−0.002−0.0010.0010.0100.4800.6576.396.313.5entire−0.0060.0030.0090.0530.6470.773−7.294.716.4TMLEoutcome−0.001−0.002−0.0000.0030.4380.642−14.389.526.9treatment−0.0040.0020.0060.0390.5720.757−24.984.327.5common−0.001−0.002−0.0010.0020.4690.657−10.790.921.2entire−0.0050.0030.0070.0430.5440.748−30.780.934.3FMoutcome−0.0050.0020.0060.0390.5490.710−24.387.128.5treatment−0.0090.0050.0140.0820.6770.832−37.778.035.1common−0.0050.0010.0060.0380.5630.713−26.385.829.1entire−0.0070.0060.0140.0820.6740.830−37.378.134.8300GCoutcome−0.000−0.0000.0000.0010.2210.532−1.994.559.8treatment−0.000−0.0000.0000.0010.2590.608−2.894.347.4common−0.000−0.0000.0000.0010.2370.539−1.294.853.5entire−0.000−0.0000.0000.0010.2410.600−3.494.053.0IPTWoutcome−0.001−0.0000.0010.0060.2390.53320.298.034.7treatment−0.0020.0000.0030.0140.3300.6154.696.029.5common−0.001−0.0000.0010.0060.2520.54113.397.436.5entire−0.0020.0000.0020.0130.3260.6077.996.628.5TMLEoutcome−0.000−0.001−0.0000.0000.2330.532−3.093.954.2treatment−0.0010.0000.0020.0090.3100.612−10.490.640.2common−0.001−0.0010.0000.0010.2490.540−1.594.648.1entire−0.0010.0000.0010.0080.2900.603−13.289.646.1FMoutcome−0.0020.0000.0020.0100.2940.552−20.288.751.6treatment−0.0030.0030.0060.0320.3890.652−39.377.053.3common−0.001−0.0000.0010.0080.3150.588−25.586.251.3entire−0.0030.0030.0060.0320.3770.644−37.477.852.2500GCoutcome−0.0000.0000.0010.0030.1680.501−0.494.881.1treatment−0.0000.0000.0010.0020.1980.573−1.094.869.0common−0.0000.0000.0000.0020.1830.505−0.794.975.0entire−0.0000.0000.0010.0040.1830.569−1.094.875.3IPTWoutcome−0.0010.0000.0010.0050.1800.50122.298.358.5treatment−0.0010.0010.0010.0070.2480.5738.196.542.3common−0.0010.0000.0010.0050.1930.50513.897.358.6entire−0.0010.0000.0010.0060.2390.56913.197.241.3TMLEoutcome−0.0000.0000.0000.0020.1770.501−0.894.776.8treatment−0.0000.0000.0000.0030.2340.571−5.992.756.1common−0.0000.0000.0000.0020.1900.505−0.594.769.7entire−0.0000.0000.0000.0030.2180.566−7.591.863.1FMoutcome−0.0010.0000.0010.0050.2190.518−17.589.870.1treatment−0.0020.0020.0030.0180.3020.598−39.876.265.5common−0.001−0.0000.0010.0050.2660.555−31.882.366.4entire−0.0020.0020.0040.0190.2890.592−37.178.366.22000GCoutcome−0.000−0.000−0.000−0.0010.0850.482−0.694.6100.0treatment0.000−0.001−0.001−0.0030.0990.550−0.694.799.8common0.000−0.001−0.001−0.0030.0920.483−0.894.799.9entire−0.000−0.000−0.000−0.0010.0910.550−0.694.799.9IPTWoutcome−0.000−0.0000.0000.0020.0900.48221.298.299.8treatment0.000−0.001−0.001−0.0020.1220.5479.396.795.1common−0.000−0.0000.0000.0010.0960.48313.597.399.7entire0.000−0.000−0.001−0.0020.1170.54614.397.595.62000TMLEoutcome−0.000−0.000−0.000−0.0010.0880.482−0.694.8100.0treatment0.000−0.001−0.001−0.0030.1160.545−2.294.498.7common0.000−0.000−0.001−0.0020.0950.483−0.394.899.9entire0.000−0.000−0.001−0.0020.1080.544−2.694.199.4FMoutcome−0.000−0.000−0.0000.0000.1290.497−29.982.999.0treatment−0.001−0.0000.0000.0030.1690.569−46.670.696.2common0.000−0.000−0.001−0.0010.2050.534−55.961.192.7entire−0.000−0.0000.0000.0020.1450.549−37.777.998.2\*MSE in the presence of an unmeasured confounder. Theoretical values: $\documentclass[12pt]{minimal}
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                \begin{document}$${\pi }_{1}=0.557,{\pi }_{0}=0.441,\theta =0.466$$\end{document}$.

Variance {#Sec13}
--------

For all methods, the outcome set led to the lowest MSE, followed closely by the common set. G-computation led to the lowest MSE and FM to the highest. In ATT, IPTW had lower MSE than TMLE. Note that the VEB was particularly high for FM in all ATE scenarios with a minimum of −17.5% (n = 500 with the outcome set). For the ATT, FM also had a higher VEB than other methods, apart from TMLE with the treatment or entire sets in sample sizes of fewer than 2000 subjects. In the presence of an unmeasured confounder, the MSE increased in all scenarios in agreement with the increase in bias. The VEBs did not change notably with an unmeasured confounder.

Coverage and error rates {#Sec14}
------------------------

G-computation produced coverage rates close to 95%, except for ATE in a small sample size leading to an anti-conservative 95% CIs with a minimum of 91.7% with the entire set under the null hypothesis. Anti-conservatives 95% CIs were also produced by FM in all scenarios, and by TMLE given a small sample size. Conversely, conservative 95% CIs were obtained when using TMLE for the ATT with the entire or the treatment sets, and when using IPTW for ATT or ATE with the outcome or the common sets.

Lending confidence to these results, the type I error was close to 5% for GC in all scenarios and may vary for other methods. The power was more impacted by the choice of the covariate set. The outcome set led to the highest power for GC.

Applications {#Sec15}
============

We illustrated our findings by using two real data sets. First, we compared the efficiency of two treatments, *i*.*e*., Natalizumab and Fingolimod, sharing the same indication for active relapsing-remitting multiple sclerosis. Physicians preferentially use Natalizumab in practice for more active disease, indicating possible confounders. Given the absence of a clinical trial with a direct comparison of their efficacy, Barbin *et al*.^[@CR53]^ recently conducted an observational study. We reused their data. Second, we sought to study barbiturates that can lead to a reduction of the patient functional status. Indeed, barbiturates are suggested in Intensive Care Units (ICU) for the treatment of refractory intracranial pressure increases. However, the use of barbiturates is associated with haemodynamic repercussions that can lead to brain ischaemia and immunodeficiency, which may contribute to the occurrence of infection. These applications were conducted in accordance with the French law relative to clinical noninterventional research. According to the French law on Bioethics (July 29, 1994; August 6, 2004; and July 7, 2011, Public Health Code), the patients' written informed consent was collected. Moreover, data confidentiality was ensured in accordance with the recommendations of the French commission for data protection (Commission Nationale Informatique et Liberté, CNIL decisions DR-2014-558 and DR-2013-047 for the first and the second application, respectively).

To define the four sets of covariates, we asked experts (D.L. for multiple sclerosis and M.L. for ICU) which covariates were causes of the treatment allocation and which were causes of the outcome, as proposed by VanderWeele and Shpitser^[@CR33]^. We checked the positivity assumption and the covariate balance (see OSI). We applied B-spline transformations for continuous variables when the log-linearity assumption did not hold.

Natalizumab versus Fingolimod to prevent relapse in multiple sclerosis patients {#Sec16}
-------------------------------------------------------------------------------

The outcome was at least one relapse within one year of treatment initiation. Six hundred and twenty-nine patients from the French national cohort OFSEP were included ([www.ofsep.org](http://www.ofsep.org)). The first part of Table [3](#Tab3){ref-type="table"} presents a description of their baseline characteristics.Table 3Baseline characteristics of patients of the two studied cohorts.A - Multiple sclerosisOverall (n = 629)First line treatmentRelapse at 1 yearNtz (n = 326)Fng (n = 303)*p*No (n = 478)Yes (n = 151)*p*Patient age, years (mean, sd)37.09.636.89.937.29.20.650537.19.736.69.20.5849Female patient (n, %)479.076.2254.077.9225.074.30.2822367.076.8112.074.20.5124Disease duration, years (mean, sd)8.56.48.06.19.06.80.05058.66.68.26.00.4809At least one relapse (n, %)526.083.6293.089.9233.076.9\<0.0001391.081.8135.089.40.0277Gd-enhancing lesion on MRI (n, %)311.049.4185.056.7126.041.60.0001240.050.271.047.00.4944EDSS score \>3 (n, %)288.045.8166.050.9122.040.30.0074212.044.476.050.30.1986Previous immunomodulatory treatment (n, %)556.088.4293.089.9263.086.80.2284424.088.7132.087.40.6672**B -- ICUOverall (n = 252)Barbiturates treatmentFavourable GOS at 3 monthsNo (n = 178)Yes (n = 74)*p*No (n = 180)Yes (n = 72)*p***Patient age, years (mean, sd)47.417.448.717.944.115.70.056550.816.438.716.9\<0.0001Female patient (n, %)89.035.358.032.631.041.90.159268.037.821.029.20.1963Diabetes (n, %)17.06.715.08.42.02.70.098915.08.32.02.80.1122Nosological entity: Severe trauma (n, %)124.049.295.053.429.039.20.040377.042.847.065.30.0012SAP ≤90 mmHg before admission (n, %)56.022.236.020.220.027.00.236846.025.610.013.90.0442Evacuation of subdural or extradural hematoma (n, %)41.016.333.018.58.010.80.130127.015.014.019.40.3878External ventricular drain (n, %)64.025.439.021.925.033.80.048648.026.716.022.20.4640Evacuation of cerebral hematoma or lobectomy (n, %)42.016.728.015.714.018.90.536234.018.98.011.10.1345Decompressive craniectomy (n, %)27.010.715.08.412.016.20.068621.011.76.08.30.4396Blood transfusion before admission (n, %)34.013.525.014.09.012.20.690326.014.48.011.10.4841Pneumonia before increased ICP (n, %)29.011.516.09.013.017.60.051919.010.610.013.90.4538Osmotherapy (n, %)112.044.475.042.137.050.00.252589.049.423.031.90.0115GCS score ≥862.024.639.021.923.031.10.123737.020.625.034.70.0183Hemoglobin, g/dL (mean, sd)11.82.311.72.212.12.50.182411.82.411.91.90.7373Platelets, counts/mm^3^ (mean, sd)206.778.0207.479.7205.174.20.8312209.083.8200.961.10.4589Serum creatinine, mmol/L (mean, sd)71.129.371.127.671.133.30.985372.432.667.918.70.2732Arterial pH (mean, sd)7.30.17.30.17.30.10.09787.30.17.30.10.6317Serum proteins, g/L (mean, sd)58.210.457.710.659.69.70.166258.010.758.89.70.5963Serum urea, mmol/L (mean, sd)5.02.55.22.74.71.80.18275.22.34.52.90.0505PaO~2~/FiO~2~ ratio (mean, sd)302.7174.0292.7154.7326.6212.90.1595282.1172.4354.2168.40.0028SAPS II score (mean, sd)47.611.447.610.747.612.90.984749.910.841.810.7\<0.0001Ntz: Natalizumab, Fng: Fingolimod, Gd: Gadolinium, MRI: Magnetic Resonance Imaging, EDSS: Expanded Disability Status Scale, SAP: Systolic Arterial Pressure, ICP: Intra-Cranial Pressure, GCS: Glasgow Coma Scale, PaO~2~/FiO~2~: arterial partial Pressure of Oxygen/Fraction of Inspired Oxygen, SAPS II: Simplified Acute Physiology Score II.

All included patients could have received either treatment. Therefore, we sought to estimate the ATE. The first part of Table [4](#Tab4){ref-type="table"} presents the results according to the different possible methods and covariate sets. The GC, IPTW and TMLE yield similar results regardless of the covariate sets considered. Thus, Fingolimod exhibits lower efficacy than Natalizumab with an OR \[95% CI\] ranging from 1.50 \[1.02; 2.21\] for IPTW with the entire set to 1.55 \[1.06; 2.28\] for GC with the common set. When using FM, the OR ranged from 1.73 \[1.19; 2.51\] with the outcome set to 1.78 \[1.23; 2.56\] with the common set. Note that, unlike IPTW, FM does not to balance all covariates in the outcome set with standardised differences higher than 10%.Table 4Results of the two applications.applicationmethodset$\documentclass[12pt]{minimal}
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                \begin{document}$$\hat{\theta }$$\end{document}$SE95% CI**A -** Multiple sclerosisGCoutcome20.328.20.4320.189\[0.062, 0.802\]treatment\*20.328.30.4360.195\[0.054, 0.819\]common\*20.328.30.4360.195\[0.054, 0.819\]entire20.328.20.4310.191\[0.056, 0.806\]IPTWoutcome21.228.80.4060.195\[0.023, 0.789\]treatment\*20.328.20.4330.191\[0.059, 0.808\]common\*20.328.20.4330.191\[0.059, 0.808\]entire21.328.90.4060.196\[0.022, 0.791\]TMLEoutcome21.228.80.4070.195\[0.025, 0.790\]treatment\*20.328.20.4330.190\[0.061, 0.806\]common\*20.328.20.4330.190\[0.061, 0.806\]entire21.128.90.4100.196\[0.026, 0.794\]FMoutcome19.129.00.5490.189\[0.178, 0.921\]treatment\*19.930.60.5750.187\[0.210, 0.941\]common\*19.930.60.5750.187\[0.210, 0.941\]entire21.131.90.5610.183\[0.201, 0.920\]**B -** ICUGCoutcome66.381.10.7780.294\[0.201, 1.354\]treatment65.381.10.8240.298\[0.240, 1.407\]common65.081.10.8360.289\[0.270, 1.402\]entire66.581.10.7690.295\[0.191, 1.347\]IPTWoutcome31.081.10.6560.356\[−0.042, 1.354\]treatment68.281.10.6930.355\[−0.002, 1.388\]common67.481.10.7290.353\[0.038, 1.421\]entire69.281.10.6450.362\[−0.064, 1.354\]TMLEoutcome66.279.60.6920.293\[0.118, 1.266\]treatment65.480.20.7580.288\[0.194, 1.322\]common64.879.90.7690.298\[0.185, 1.354\]entire66.479.40.6680.285\[0.109, 1.228\]FMoutcome73.881.10.4190.342\[−0.252, 1.090\]treatment67.281.10.7390.337\[0.078, 1.399\]common65.181.10.8310.336\[0.173, 1.490\]entire66.281.10.7820.336\[0.123, 1.442\]\*Treatment and common sets contain same covariates. *π*~0~: Percentage of event in the Natalizumab (or control) group, *π*~1~: Percentage of event in the Fingolimod (or Barbiturates) group, SE: standard error.

Overall, the confounder-adjusted proportion of patients with at least one relapse within the first year of treatment was lower in the hypothetical world where all patients received Natalizumab (approximately 20% and varying slightly depending on method and set of covariates) than one in which all patients received Fingolimod (approximately 28%). This difference of approximately 8% is clinically meaningful and suggests the superiority of Natalizumab over Fingolimod to prevent relapses at one year. This result was concordant with the recent clinical literature^[@CR53],[@CR54]^.

Impact of barbiturates in the ICU on the functional status at three months {#Sec17}
--------------------------------------------------------------------------

We define an unfavourable functional outcome by a 3-month Glasgow Outcome Scale (GOS) lower than or equal to 3. We used the data from the French observational cohort AtlanREA ([www.atlanrea.org](http://www.atlanrea.org)) to estimate the ATT of barbiturates because physicians recommended these drugs to a minority of severe patients. The second part of Table [3](#Tab3){ref-type="table"} presents the baseline characteristics of the 252 included patients.

The second part of Table [4](#Tab4){ref-type="table"} presents the results according to the different possible methods and covariate sets. G-computation and TMLE lead to the conclusion of a significant negative effect of barbiturates regardless of the covariate set considered with an OR \[95% CI\] ranging from 0.43 \[0.25; 0.76\] for GC with the common set to 0.51 \[0.29; 0.90\] for TMLE with the entire set. By contrast, the results were discordant when using different covariate sets for IPTW and FM. We report, for instance, OR estimates obtained by FM ranging from 1.520 with the outcome set to 2.300 with the common set. In line with the simulation study, the estimated standard errors were higher for these methods (0.294 and 0.293 for GC and TMLE when the outcome set was considered, respectively) leading to lower power. Note also that standardised differences were higher than 10% for the IPTW with the entire set (see OSI) and for FM with the outcome, the treatment and the entire sets.

Depending on the methods and sets of covariates included, we estimated that from 18% to 20% of patients treated with barbiturates had an unfavourable GOS at three months. If these patients had not received barbiturates, the methods estimate that from 30% to 35% would have had an unfavourable GOS at three months. For the patients, this difference is meaningful but full clinical relevance depends also on the effect of barbiturates on other clinically relevant outcomes, such as death or ventilator-associated pneumonia. However, the results obtained by GC or TMLE differ with those obtained by Majdan *et al*.^[@CR55]^, who did not find any significant effect of barbiturates on the GOS at six months. Two main methodological reasons can explain this difference: the GOS was at six months rather than three months post-initiation, and the authors used multivariate logistic regression leading to a different estimand.

Discussion {#Sec18}
==========

The aim of this study was to better understand the different sets of covariates to consider when estimating the marginal causal effect.

The results of our simulation study, limited to the studied scenarios, highlight that the use of the outcome set was associated with the lower bias and variance, principally when associated with GC, for both ATE and ATT. As expected, an unmeasured confounder led to increased bias, regardless of method employed. Although we do not report an impact on the variance, the effect's over- or under-estimation leads to the corresponding over- or under-estimation of power and compromises the validity of the causal inference.

The performance of FM is lower than that of the other studied methods, especially for the variance. Our results were in line with King and Nielsen^[@CR56]^, who argued for halting the use of PS matching for many reasons such as covariate imbalance, inefficiency, model dependence and bias. Nonetheless, Colson *et al*.^[@CR17]^ found slightly higher MSE for GC than FM. Their more simplistic scenario, with only two simulated confounders leading to little covariate imbalance, could explain the difference with our results. Moreover, is unclear whether they accounted for the matched nature of the data, as recommended by Austin and Stuart^[@CR16]^ or Gayat *et al*.^[@CR50]^.

While DRE offers protection against model misspecification^[@CR23],[@CR34],[@CR36]^, our simulation study resulted in the finding that GC was more robust to the choice of the covariate set than the other methods, TMLE included. This result was particularly important when the treatment set was taken into account, which fits with the results of Kang and Schafer^[@CR35]^: when both the PS and the Q-model were misspecified, DRE had lower performance than GC. Furthermore, GC was associated with lower variance than DRE in several simulation studies^[@CR13],[@CR17],[@CR35]^, which accords with our results.

The first application to multiple sclerosis (ATE) illustrated similar results between the studied methods. In contrast, the second application (ATT) to severe trauma or brain-damaged patients showed different results between the methods. In agreement with simulations, the estimations obtained with GC or TMLE were similar in terms of logOR estimation and variance regardless of the covariate set considered. Estimations obtained with IPTW or FM were highly variable, depending on the covariate set employed: some indicated a negative impact of barbiturates and others did not. These results also tended to demonstrate that GC or TMLE had the highest statistical power. Variances obtained by parametric simulations or by bootstrap resampling were similar (results not displayed).

One can, therefore, question the relative predominance of the PS-based approach compared to GC, although there are several potential explanations. First, there appears to be a pre-conceived notion according to which multivariable non-linear regression cannot be used to estimate marginal absolute and relative effects^[@CR57]^. Indeed, under logistic regression, the mean sample probability of an event is different from the event probability of a subject with the mean sample characteristics. Second, while there is an explicit variance formula for the IPTW^[@CR58]^, the equivalent is missing for the GC. The variance must be obtained by bootstrapping, simulation or the delta method. Third, several didactic tutorials on PS-based methods can be found, for instance^[@CR59]--[@CR61]^.

We still believe that PS-based methods may have value when multivariate modelling is complex, for instance, for multi-state models^[@CR62]^. In future research, it would be interesting to examine whether the use of potentially better settings would provide equivalent results, such as the Williamson estimator for IPTW^[@CR58]^, the Abadie-Imbens estimator for PS matching^[@CR63]^, or bounded the estimation of TMLE, which can also be updated several times^[@CR36]^. We also emphasise that we did not investigate these methods when the positivity assumption does not hold. Several authors have studied this problem^[@CR13],[@CR25],[@CR35],[@CR36],[@CR64]^. G-computation was less biased than IPTW or DRE except in Porter *et al*.^[@CR36]^, where the violation of the positivity assumption was also associated with model misspecifications. The robustness of GC to non-positivity could be due to a correct extrapolation into the missing sub-population, which is not feasible with PS^[@CR1]^. Other perspectives of this work are to extend the problem to i) time-to-event, continuous or multinomial outcomes and ii) multinomial treatment. However, implementing GC using continuous treatment raises many important considerations concerning the research question and resulting inference^[@CR64]^.

To facilitate its use in practice, we have implemented the estimation of both ATE and ATT, and their 95% CI, from a logistic model in the existing R package entitled *RISCA* (available at cran.r-project.org/web/packages/RISCA). We provide an example of R code in the appendix. Note that the package did not consider the inflation of the type I error rate due to the modelling steps of the Q-model. Users also have to consider novel strategies for post-model selection inference.

In the applications, we classified covariates into sets based on experts knowledge^[@CR33]^. However, several statistical methods can be useful when no clinical knowledge is available. Heinze *et al*.^[@CR65]^ proposed a review of the most used, while Witte and Didelez^[@CR66]^ reviewed strategies specific to causal inference. Alternatively, data-adaptive methods have recently been developed, such as the outcome-adaptive LASSO^[@CR67]^ to select covariates associated with both the outcome and the treatment allocation. Nevertheless, according to our results, it may be preferable to focus on constructing the best outcome model based on the outcome set. For instance, the consideration of a super learner^[@CR68],[@CR69]^, merging models and modelling machine learning algorithms may represent an exciting perspective^[@CR70]^.

Finally, we emphasise that the conclusions from our simulation study cannot be generalised to all situations. They are consistent with the current literature on causal inference, but theoretical arguments are missing for generalisation. Notably, our results must be considered in situations where both the PS and the Q-model are correctly specified and where positivity holds.

To conclude, we demonstrate in a simulation study that adjusting for all the covariates causing the outcome improves the estimation of the marginal causal effect (ATE or ATT) of a binary treatment in a binary outcome. Considering only the covariates that are a common cause of both the outcome and the treatment is possible when the number of potential confounders is large. The strategy consisting of considering all available covariates, *i*.*e*., no selection, did not decrease the bias but significantly decreased the power. Amongst the different studied methods, GC had the lowest bias and variance regardless of covariate set considered. Consequently, we recommend that the use of the GC with the outcome set, because of its highest power in all the simulated scenarios. For instance, at least 500 individuals were necessary to achieve a power higher than 80% in ATE, with a theoretical OR at 2, and a percentage of treated subjects at 50%. In ATT, we needed larger sample size to reach a power of 80% because the estimation considers only the treated patients. With 2000 individuals, all the studied methods with the outcome set led to a bias close to zero and a statistical power superior to 95%.
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